ESMO Breast 2024 | Advancements in immunotherapy for high-risk HR+ breast cancer

Sung-Bae Kim, MD, PhD, Asan Medical Center, Seoul, South Korea, discusses the role of immune checkpoint inhibitors in hormone receptor-positive (HR+) breast cancer. Recent findings from the I-SPY 2 trial (NCT01042379) show that combining pembrolizumab with chemotherapy nearly doubles the pathological complete response (pCR) rate in patients with high-risk HR+ early breast cancer. Integrating CDK4/6 inhibitors in adjuvant and neoadjuvant settings further enhances efficacy. Identifying patients who benefit most while managing potential toxicities is essential. This interview took place at the 2024 European Society for Medical Oncology (ESMO) Breast Cancer Annual Congress in Berlin, Germany.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.